Hot Investor Mandate 2: Taiwan Cross Border VC Seeks Medical Devices, Diagnostic Tools, Digital Health, Healthcare IoT Technologies

~ Next Phase Admin ~ Leave a comment

An early-stage venture capital firm based in Taipei, Taiwan is actively investing in the life sciences space. Formed by a group of successful entrepreneurs, the firm specializes in incubation, seed and early venture investments in technology-heavy sectors. The firm is currently investing from its $35 million fund that closed in 2016. Typical equity allocations range from $500K to $3M in seed to series A rounds. The firm generally leads a financing round but is also open to syndication. The firm is currently seeking opportunities from Taiwan and the United States.

Within life sciences, the firm considers medical devices, IVD tools, digital health and healthcare internet of things (IoT). Within medtech, the firm is looking for early stage projects with solid unmet medical need. On-market products are less of interest. The firm is open to all risk levels and all disease indications. The firm is also interested in material science and agricultural biotech.

The firm is an active investor. The firm can work with incomplete teams, assist companies with regulatory strategy and product definition, and help overseas businesses find manufacturing partners in Taiwan. The firm typically takes a board seat in a portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: Joint Initiative Launched by a Leading Pharma and VC Firm Invests in Digital Health Companies with USA Focus

~ Next Phase Admin ~ Leave a comment

A digital health investment company launched in 2016 by a leading pharma and venture capital firm in the industry focuses on the digital health space ranging from therapeutics to diagnostic solutions in areas such as: precision medicine, behavioral health, wearables, and data analytics. The firm is seeking to make 6-8 new investments within the next two years. The firm’s investments range dependent on the opportunity, and focuses on investing in Seed to Series A rounds. For earlier stage companies, the firm has the ability to both lead and co-invest. The firm focuses on companies based in the U.S., but is open to invest globally.

The firm focuses on digital health technologies and solutions that aim to improve patient care and lifestyle. The firm is especially interested in technology with a software component, such as those that control patient care through monitoring medications and therapies, as well as technology with a big data component. The firm will only look at devices if they have an information component and/or generate data. The firm is also interested in technology with machine-learning applications. The firm is not interested in pure EMR or hospital IT systems. Based on all the criteria, the firm is indication agnostic.

The firm is a very active investor that seeks to be fully involved in their portfolio companies. The firm will take a board seat after the investment and will help companies fill management teams, if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 4: Germany-Based CVC with a Global Presence Invests in Innovative Medical Technologies Globally, Including Imaging & PoC and In Vitro Diagnostics

~ Next Phase Admin ~ Leave a comment

A corporate venture firm is headquartered in Munich, Germany, with additional offices worldwide. The fund invests in medical technology companies that are strategically relevant to the corporate’s interests. Investments in equity rounds range from $1-5 million and are made worldwide.

The firm’s primary focuses within healthcare are medical imaging (including both equipment and software) and diagnostics (particularly point of care diagnostics and molecular diagnostics). In these sectors, the firm focuses on products used in a hospital setting. The firm also invests in digital health solutions that add value to imaging and diagnostics, such as data-as-a-service products. The firm is potentially interested in medical robotics. The firm will invest in any medical indication area, and only invests in companies that have attained proof of concept data for their product, with a preference for companies that have a product on the market that can demonstrate traction and revenue.

The firm generally does not attach strategic rights to an investment other than the right to be informed if the company is seeking a buyer. The firm requires a board seat or a board observer in each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

RESI Boston Summer, June 4, 2018 – Program Guide Is Here!

~ Next Phase Admin ~ Leave a comment

By Nono Hu, Director of Marketing, LSN

In 4 days, The Redefining Early Stage Investments (RESI) Conference will kick off a bustling week for the global healthtech industry in Boston. At RESI Boston, over 300 investors will be under one roof in search of compelling connections with early stage companies.

Check out the program guide now to plan for a productive day at RESI packed with partnering meetings, innovative technologies, and up-to-date investment knowhow.

See you at RESI on June 4th at the Boston Marriott Copley Place!

Life Science Nation Launches RESI Healthtech Week, Sept. 5-7, 2018

~ Next Phase Admin ~ Leave a comment

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series & RESI Healthtech Week

The inaugural RESI Healthtech Week (RESI HW) launches on September 5th at the Boston Marriott Copley Place with a new conference – the First Coast Innovator’s Gathering, where incubators, accelerators, tech transfer, university translation initiatives, hospitals, research labs and their constituents from DC, MD, PA, NJ, NY, RI, CT and MA (the first coast) will gather for the first time in one location to get on the radar screens of potential global partners. The First Coast Innovator’s Gathering is followed by the RESI Global Partnering Conference, September 6th, and the Entrepreneur’s Academy Workshop Series, September 7th.

LSN’s established network of early-stage global investors attend RESI Conference Series to source, engage and allocate funds to startup firms across the silos of biotech, medtech, diagnostics, and digital health. In addition, we present the RESI Healthtech Week!

“The First Coast is blessed with an amazing amount of technological assets addressing unmet medical needs across the entire healthcare spectrum. They need to get in front of global investors,” says Dennis Ford, CEO at Life Science Nation. This includes over 100 incubators, accelerators, tech transfer, university translation initiatives, hospitals, and research labs each with aggregate portfolios of 1000 or more assets.

Chuck Stetson, CEO of Stetson Family Office, is a Title Sponsor of the First Coast Innovator’s Investor Gathering on September 5th, and the RESI Global Investor Conference on September 6th. Stetson is pioneering a new, nonprofit, evergreen, endowment model for early-stage global companies within technology-rich innovation hubs. “It is time to address the developmental ‘valley of death’ and muster state-of-the-art resources to bring breakthrough technologies to market faster,” Stetson stated.

LSN invites the technology hubs, and their scientist/entrepreneurs, of the First Coast to take advantage of this inaugural launch. LSN created an affordable registration price that will facilitate more startups attending the three-day event. “We had to get the price point right as the early stage folks have been priced out of most of the other conferences,” said Ford. Register for the event at www.resihealthtechweek.com/.

Qualifying First Coast day 1 registrants are the northeast corridor incubators, accelerators, tech transfer, university translation initiatives, hospitals, research labs and their constituents as well as the investors and partners that seek them. Day 2 and 3 are open to all global attendees – scientist-entrepreneurs, fundraising CEOs, investors, channel partners and service providers.

RESI Spotlight: Investors Focusing on Innovative Technologies For Mental & Behavioral Health

~ Next Phase Admin ~ Leave a comment

By Christine A. Wu, Senior Research Analyst, LSN

chrsitine

While mental and behavioral health conditions are highly prevalent, they are also often stigmatized. In the healthcare technology arena, this indication area has been on the rise in both excitement and innovation. According to the World Health Organization, one out of four people in the world suffer from a mental or neurological disorder, including a total of about 450 million people with mental disorders. Even as one of the leading causes of ill-health and disability worldwide, mental illness carries with it stigma, discrimination, and neglect, preventing patients from admitting the need for help, reaching for help or having the accessibility to resources for when they do. In a society that shies away from vulnerability, it becomes easy for us to not embrace the need for mental health or fully understand how to prevent future cases.

Industry and investors have responded; with the growth of the digital health vertical, the amount of capital invested in the mental and behavioral healthcare space has increased significantly. This year, the industry has seen deals as high as $40M in digital health platforms streamlining patients and mental health clinicians, mobile apps with professional coaching, and software solutions to overcome anywhere from anxiety and depression to eating disorders and substance abuse. As chronic diseases such as diabetes and inflammatory bowel disease can be debilitating for patients both medically and psychologically, behavioral health solutions include disease management IT platforms to monitor and improve treatment adherence. With the aim to treat individuals holistically, such platforms connect patients, mental health professionals, and medical physicians, tracking the patient’s physical and mental health as the disease progresses.

At RESI Boston Summer on Monday, June 4th, the LSN team is launching an initiative to highlight investment in mental and behavioral health with a new expert panel of VCs, pharma, hospital and healthcare systems.

Moderated by Julie Papanek Grant, Partner at Canaan Partners, the panel includes:

  • Justin Baker, Scientific Director, The McLean Institute for Technology in Psychiatry
  • Ken Duckworth, Senior Medical Director for Behavioral Health, Blue Cross Blue Shield of MA
  • Robert Garber, Partner, 7wire Ventures
  • Eric Schaeffer, Senior Director, Neuroscience Innovation, Johnson & Johnson Innovation

Panelists will provide their diverse perspectives of industry (and academia) trends in mental and behavioral health, its future outlook, and global impact.

The LSN team has also slated a handful of digital health companies in mental and behavioral health for the RESI Innovation Challenge.

Register for RESI and be sure to meet and learn both the investor side and company side of this up-and-coming space!

 

Hot Investor Mandate 1: West Coast-Based Family Office Invests Up to $10M Into Early-Stage Therapeutics, Devices, and Tools Companies

~ Next Phase Admin ~ Leave a comment

A family office based in the West Coast invests in primarily early-stage (seed, Series A, Series B) companies with truly innovative technologies with a typical investment size of $2-10M per company. The firm will generally lead investments and invests globally with no geographic preference.

The firm is agnostic across life science sectors, including therapeutics, devices, and tools, but will not consider Healthcare IT or digital health technologies. The firm focuses on early stage preclinical to clinical-stage technology, though may be open to commercial-stage technology depending on the opportunity.

The firm is seeking companies with founders who have big ambitions, and a demonstrated ability to sell their team, investors, and partners on their vision. Previous startup experience is a big plus, but not required, and they will invest in young and first-time entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.